IXICO plc – Half Yearly Report to 31 March 2019

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces its unaudited interim results for the six months ended 31 March 2019.


Commercial and Operational

·    £5.2M new and expanded contracts won across H1 2019.

·    Strong contracted order book of £21.2M* as at 31 March 2019.

·    Broadened expertise in neurological disease areas and diversification of biopharmaceutical clients.

·    Chosen as partner for King’s College London’s UK Government-funded Medical Imaging & Artificial Intelligence Centre.


·    Revenue of £3.4M; 22% increase on prior period (H1 2018: £2.8M**).

·    Revenue excluding foreign exchange of £3.3M*; 21% increase on prior period (H1 2018: £2.7M**).

·    Gross margin expanded by +610 bps** over H1 2018 to 66.3%.

·    EBITDA of £0.1M driven by strong operational leverage at gross margin level (H1 2018: negative £0.4M**).

·    Operating profit of £0.1M (H1 2018: loss of £0.5M**).

·    Profit per share of 0.5p (H1 2018: negative 1.5p**).

·    Closing cash of £7.5M.


*Calculated using the fixed foreign exchange at the time of contract signing for each individual multi-year contract.

**Adjusted to reflect the adoption of IFRS 15 ‘Revenue from Contracts with Customers’.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...